Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease

被引:22
|
作者
Holm, Thomas Lindebo [1 ]
Tornehave, Ditte [1 ]
Sondergaard, Henrik [1 ]
Kvist, Peter Helding [1 ]
Sondergaard, Bodil-Cecilie [1 ]
Hansen, Lene [1 ]
Hermit, Mette Brunsgaard [1 ]
Holgersen, Kristine [2 ]
Vergo, Sandra [1 ]
Frederiksen, Klaus Stensgaard [1 ]
Haase, Claus [1 ]
Lundsgaard, Dorthe [1 ]
机构
[1] Novo Nordisk AS, Global Res, Malov, Denmark
[2] Novo Nordisk LIFE In Vivo Pharmacol Ctr, Frederiksberg, Denmark
关键词
COMMON GAMMA-CHAIN; T-CELLS; TH17; CELLS; DOWN-REGULATION; INTERLEUKIN-21; RECEPTOR; COLITIS; PROLIFERATION; EXPRESSION; MODEL;
D O I
10.1155/2018/5962624
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim. Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. Methods. In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4(+)CD45RB(high)IL-21R(-/-) T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex. Results. In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2(-/-) mice receiving CD4(+)CD45RB(high)IL-21R(-/-) T cells developed less severe colitis compared to Rag2(-/-) mice receiving CD4(+)CD45RB(high)IL-21R(+/+) T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis. Conclusion. Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Plasma IgA as a biomarker and IL-21 as a potential therapeutic target in Inflammatory Bowel Disease
    Tsai, T.
    Hsu, J. L.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I981 - I982
  • [2] IL-21 as a therapeutic target in inflammatory disorders
    Di Fusco, Davide
    Izzo, Roberta
    Figliuzzi, Michele M.
    Pallone, Francesco
    Monteleone, Giovanni
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (11) : 1329 - 1338
  • [3] Psoriasis, from Pathogenesis to Therapeutic Strategies: IL-21 as a Novel Potential Therapeutic Target
    Botti, Elisabetta
    Spallone, Giulia
    Caruso, Roberta
    Monteleone, Giovanni
    Chimenti, Sergio
    Costanzo, Antonio
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (10) : 1861 - 1867
  • [4] IL-21, a Potential Target of Active Rejection in Renal Transplantation
    Shen, J.
    Wang, R.
    Guo, L.
    Lv, J.
    Wu, J.
    Chen, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 629 - 629
  • [5] IL-21 Production and Function in Peripheral Immune Cells From Crohn's Disease Patients
    Cox, Jennifer H.
    Thomas, Evan
    Wu, Rebecca P.
    Valliant-Saunders, Kem
    Hussell, Scott
    Smith, Patricia
    Stucky, Jason
    Blasius, Amanda
    Serikawa, Kyle
    Blumberg, Hal
    Levin, Steve
    Lundsgaard, Dorthe
    GASTROENTEROLOGY, 2013, 144 (05) : S819 - S819
  • [6] The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease
    Sivignon, Adeline
    Bouckaert, Julie
    Bernard, Julien
    Gouin, Sebastien G.
    Barnich, Nicolas
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (09) : 837 - 847
  • [7] IL-21 AS A NEW TARGET FOR IMMUNOSUPPRESSIVE THERAPIES
    Baan, Carla C.
    TRANSPLANTATION, 2020, 104 (09) : S144 - S144
  • [8] IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials
    Koh, Choong-Hyun
    Kim, Byung-Seok
    Kang, Chang-Yuil
    Chung, Yeonseok
    Seo, Hyungseok
    IMMUNE NETWORK, 2024, 24 (01)
  • [9] IL-21 and Sjogren's syndrome
    Scofield, R. Hal
    ARTHRITIS RESEARCH & THERAPY, 2011, 13 (06)
  • [10] IL-21 and IL-21 Receptor (IL-21R): Potential Targets for Immunotherapy in Highly Sensitized Kidney Transplant Patients
    Tavana, Reza
    Liu, Shuqing
    Tchervenkov, Jean
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 35 - 35